Published: 11 June 2021
Author(s): Sake J. van der Wall, Gregory Y.H. Lip, Christine Teutsch, Oskars Kalejs, Philippe Lyrer, Christian Hall, Sergio J. Dubner, Hans-Christoph Diener, Jonathan L. Halperin, Chang Sheng Ma, Kenneth J. Rothman, Kristina Zint, Dongmei Zhai, Menno V. Huisman, GLORIA-AF Investigators

Non vitamin-K-antagonist oral anticoagulants (NOACs) have emerged as preferred treatment over vitamin K antagonists (VKAs) for the prevention of stroke in patients with nonvalvular atrial fibrillation (AF)[1, 2]. However, prospective observational data on clinical NOAC use during cardiovascular interventions are limited.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.